EAM
FULC icon

Exome Asset Management’s Fulcrum Therapeutics FULC Stock Holding History

Exome Asset Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-20,000
Closed -$138K – 84
2025
Q2 		$138K Buy
+20,000
New +$107K 0.1% 61

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Exome Asset Management's FULC Position: Q1 2026 in Review

Exome Asset Management sold out of Fulcrum Therapeutics (FULC) in Q1 2026, closing a stake of 92,055 shares — an estimated $1.04M sold.

Exome Asset Management first reported a position in FULC in Q2 2024 and held it in 6 quarters. The position peaked at $3.06M in Q2 2025. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Exome Asset Management reported no remaining Fulcrum Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Exome Asset Management sold 92,055 Fulcrum Therapeutics shares in Q1 2026, an estimated $1.04M.
  • Exome Asset Management first reported a position in Fulcrum Therapeutics in Q2 2024 and held it in 6 quarters.
  • Exome Asset Management's Fulcrum Therapeutics position peaked at $3.06M in Q2 2025.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Exome Asset Management's 13F filing for Q1 2026, filed 15 May 2026.